Liraglutide
A GLP-1 receptor agonist approved by the FDA under brand names such as Victoza and Saxenda for specific medical indications.
What it is
Liraglutide is the elder statesman of the GLP-1 class — a daily-injection GLP-1 receptor agonist, FDA-approved as Victoza for type 2 diabetes and Saxenda for weight management, with years of post-market history behind it.
Its trial record includes cardiovascular-outcome data, and its weight-loss effect, while smaller on average than semaglutide's or tirzepatide's, is well characterized. Generic versions have begun arriving, which increasingly makes it the affordability conversation within the approved GLP-1 family.
What researchers have actually studied it for
Type 2 diabetes and weight management — approved indications with large trials, cardiovascular-outcome data and long post-market experience.
How it works
Like its successors, liraglutide activates the GLP-1 receptor — slowing gastric emptying, promoting satiety and glucose-dependent insulin release. Its fatty-acid modification buys roughly a day of action rather than a week, hence daily injection.
Where it came from
Approved for diabetes in 2010 and for weight management in 2014, liraglutide was the drug that proved chronic GLP-1 therapy for obesity was viable — the commercial and clinical groundwork everything since built on. Its LEADER trial was also the class's first major cardiovascular-outcome win.
What the research record actually contains
- LEAD program: RCTs establishing glycemic efficacy in type 2 diabetes.
- SCALE program: placebo-controlled obesity trials, high-single-digit average weight reduction.
- LEADER trial: cardiovascular-outcome benefit in high-risk type 2 diabetes.
- Fifteen years of post-market experience — the longest safety record in the class.
What's known about risks
The best-characterized safety profile in the class, by tenure: GI effects lead, with the same gallbladder, pancreatitis and thyroid-warning caveats as its successors. Its long real-world record is its distinctive safety asset.
Where it stands legally
Prescription-only; generic liraglutide has been entering the US market, a first for the GLP-1 class. The generic route runs through the same pharmacies and prescribers — it changes price, not process.
Worth asking a licensed provider
- 1.Does generic liraglutide meaningfully change the cost equation for me versus newer weekly options?
- 2.Is a daily injection realistic for my adherence, or does weekly dosing matter more than price?
- 3.How do the average-result differences across the class apply to my goals?